Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02119819 · ClinicalTrials.gov registry record · Phase 2
A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes
A Phase 2 study of Diabetes Mellitus, Type 2, sponsored by OPKO Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 420
- Enrollment target
- 20
- Study locations
NCT02119819 is a Phase 2 study of Diabetes Mellitus, Type 2 that has completed, run by OPKO Health. The registered enrollment target is 420 participants, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT02119819, a Phase 2 study of Diabetes Mellitus, Type 2, has completed, sponsored by OPKO Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 420 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to compare the safety and effectiveness of the study drug known as LY2944876 to exenatide extended-release and placebo in participants with type 2 diabetes mellitus. All drugs will be given by an injection under the skin. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry. Participants' involvement in the study is expected to last about 30 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG LY2944876
- DRUG Exenatide extended-release
Study Locations (20)
California
- John Muir Physician Network Clinical Research Center - Concord
- Valley Endocrine, Fresno - Fresno
- National Research Institute - Los Angeles
- Desert Medical Group Inc - Palm Springs
- Artemis Institute for Clinical Research - San Diego
- Encompass Clinical Research - Spring Valley
Florida
- Meridien Research - Bradenton
- M & O Clinical Research, LLC - Fort Lauderdale
- Suncoast Research Group, LLC - Miami
- Suncoast Clinical Research - New Port Richey
- Compass Research - Oviedo
- Clinical Research of Central Florida - Winter Haven
Missouri
- Mercy Medical Research Institute - Springfield
- St John's Mercy Medical Center - St Louis
- Mercy Health Research - Washington
Hawaii
- University of Hawaii - Honolulu
- East West Medical Institute - Honolulu
Idaho
- Rocky Mountain Diabetes and Osteoporosis Center - Idaho Falls
Iowa
- Iderc, P.L.C. - Des Moines
Kansas
- Cotton O'Neil Diabetes and Endocrinology Center - Topeka
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02119819
The ClinicalTrials.gov registry entry for NCT02119819 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (91% lower). The listed sponsor is OPKO Health, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT02119819 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT02119819 about?
NCT02119819 is a clinical study titled "A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes". The main purpose of this study is to compare the safety and effectiveness of the study drug known as LY2944876 to exenatide extended-release and placebo in participants with type 2 diabetes mellitus. All drugs will be given by an injection under the skin. Participants remain on stable doses of metfo...
What is the current status of trial NCT02119819?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 420 participants. The study started on 2014-04. Estimated completion is 2015-10.
What conditions does trial NCT02119819 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT02119819?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), LY2944876 (DRUG), Exenatide extended-release (DRUG).
Who is sponsoring clinical trial NCT02119819?
This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02119819 being conducted?
This trial has 20 study locations across California, Florida, Hawaii, Idaho, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DETERMINE: Detemir vs NPH
RECRUITING · Phase 2
-
MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men
RECRUITING · Phase 2
-
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RECRUITING · Phase 2
-
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
RECRUITING · Phase 2
-
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.